The biopharmaceutical industry is witnessing a recovery in funding during 2026 after several years of constrained capital availability. However, the rebound is being driven largely by investments in later-stage, lower-risk assets, while early-stage innovation continues to struggle for funding, according to GlobalData, a leading intelligence and productivity platform.

GlobalData's State of the Biopharmaceutical Industry 2026 (Mid-Year Update) highlights that mergers and acquisitions have led the recovery as major pharmaceutical companies seek to strengthen their pipelines ahead of a looming patent cliff. Among the most significant transactions this year are Eli Lilly's acquisition of Centessa Pharmaceuticals for $7.8 billion and Sun Pharmaceutical's $11.75 billion acquisition of Organon.

The trend extends beyond M&A activity. The biopharmaceutical IPO market has also reopened, supported by sizeable public offerings from companies such as Kailera Therapeutics, which raised $718.8 million, and Generate Biomedicines, which secured $400 million. Venture capital investments have similarly favored later-stage funding rounds over early discovery and preclinical-stage programs.

George El-Helou, Pharma Strategic Intelligence Analyst at GlobalData, said, “Following years of market volatility, investors and acquirers have shown a clear preference for assets with reduced development risk. While the biotech funding thaw is real, allocation is hyper-selective; capital is strictly flowing to late-stage assets with clear clinical proof of concept, leaving early-stage platforms stranded in a highly constrained financing environment.”

The funding challenges are particularly acute for early-stage biotech companies that have limited access to alternative sources of capital. 

The situation was further complicated by a temporary lapse in authorization of the US Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs between October 2025 and April 2026.